-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Highlights from The European Society of Intensive Care Medicine 2024
- Share
- Tweet
- Share on Facebook
- Share
A video highlighting Volition’s attendance at the European Society of Intensive Care Medicine Congress.
Featuring:
- Interview with Professor Djillali Annane (Professor of Medicine, University Paris Saclay-UVSQ, France, Director, Prometheus Comprehensive Sepsis Centre)
- Interview with Dr. Andrew Retter (Clinical Lead in Intensive Care, ECMO & Thrombosis, Chief Medical Officer, Volition)
- Highlights from Volition’s ‘NETs: Casting a new light on sepsis management’ Satelite Symposium
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields